Caroline Ryan
Centers for Disease Control and Prevention
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Caroline Ryan.
Sexually Transmitted Diseases | 2003
Sevgi O. Aral; Janet S. St. Lawrence; Lilia Tikhonova; Emma Safarova; Kathleen A. Parker; Anna Shakarishvili; Caroline Ryan
Background Increased poverty, unemployment, and migration place the Russian population at high risk for sexually transmitted infections (STIs). A qualitative study was undertaken to clarify the organization of sex work and describe the likely contributions of different types of sex work to disease transmission. Goal The goal of the study was to describe the social-organizational patterns of sex work in Moscow, Russia. Study Design Four qualitative data collection methods were used: semistructured telephone interviews, semistructured face-to-face individual and group interviews with key informants, systematic and unobtrusive naturalistic observations, and geomapping. Results Intermittent, truck stop, and railway station sex workers may be the most important groups in the dissemination of STIs. Sex work is widely disseminated throughout the city. Identifiable positions in the social organization of street sex work include pimps, assistant female pimps, guards, drivers, “indicators,” the sex workers themselves, and recruitment “pluckers.” Conclusion The Moscow sex market may be an adjustive response of the social system to the economic pressures in Russia. Sex work in Moscow has great potential for disseminating STIs throughout Russia and beyond. Understanding of these issues may enhance the impact of STI prevention programs.
Clinical Infectious Diseases | 2005
Gabriela Paz-Bailey; Mafiz Rahman; Cheng Chen; Ronald C. Ballard; Howard Moffat; Tom Kenyon; Peter H. Kilmarx; Patricia A. Totten; Sabina G. Astete; Marie-Claude Boily; Caroline Ryan
BACKGROUND In recent years, increasing evidence has accumulated that suggests the majority of cases of genital ulcer disease in sub-Saharan Africa are due to viral and not bacterial infections. Although many cross-sectional studies support such a trend, few serial cross-sectional data are available to show the evolution of genital ulcer disease over time. METHODS We surveyed the prevalence of sexually transmitted diseases (STDs) among patients with STD symptoms and women recruited from family planning clinics in 3 cities in Botswana in 2002 and compared our findings with those from a survey of a similar population conducted in 1993. RESULTS The observed proportion of cases of genital ulcer disease due to chancroid decreased from 25% in 1993 to 1% in 2002, whereas the proportion of ulcers due to herpes simplex virus increased from 23% in 1993 to 58% in 2002. Although the proportion of ulcers due to syphilis was similar for both surveys, the rate of positive serologic test results for syphilis among patients with genital ulcer disease decreased from 52% in 1993 to 5% in 2002. During this period, decreases in the prevalence of gonorrhea, syphilis-reactive serologic findings, chlamydial infection, and trichomoniasis were also detected among patients with STDs and women from family planning clinics. These changes remained significant after estimates were adjusted for the sensitivity and specificity of diagnostic tests. CONCLUSIONS Our findings suggest a decrease in the prevalence of bacterial STDs and trichomoniasis, a reduction in the proportion of ulcers due to bacterial causes, and an increase in the proportion of ulcers due to herpes simplex virus during the period 1993-2002. These changes should be taken into consideration when defining new guidelines for the syndromic management of genital ulcer disease.
JAMA | 2010
William Coggin; David Jamieson; Heidi Mihm; Reuben Granich; Phillip Savio; Michael Hope; Caroline Ryan; Michele Moloney-Kitts; Eric Goosby; Mark Dybul
CONTEXT One of the biggest hurdles to the rapid scale-up of antiretroviral therapy in the developing world was the price of antiretroviral drugs (ARVs). Modification of an existing US Food and Drug Administration (FDA) process to expedite review and approval of generic ARVs quickly resulted in a large number of FDA-tentatively approved ARVs available for use by the US Presidents Emergency Plan for AIDS Relief (PEPFAR). OBJECTIVE To evaluate the uptake of generic ARVs among PEPFAR-supported programs in Guyana, Haiti, Vietnam, and 13 countries in Africa, and changes over time in ARV use and costs. DESIGN, SETTING, AND PARTICIPANTS An annual survey from 2005 to 2008 of ARVs purchased in 16 countries by PEPFAR implementing and procurement partners (organizations using PEPFAR funding to purchase ARVs). MAIN OUTCOME MEASURES Drug expenditures, ARV types and volumes (assessed per pack, a 1-month supply), proportion of generic procurement across years and countries, and cost savings from generic procurement. RESULTS ARV expenditures increased from
Sexually Transmitted Diseases | 2007
Rachel N. Bronzan; Dan Mwesigwa-Kayongo; Diane Narkunas; George P. Schmid; Graham Neilsen; Ronald C. Ballard; Pascale Karuhije; James Ddamba; Eric Nombekela; Gideon Hoyi; Pumla Dlali; Nomalanga Makwedini; H Glenda Fehler; John M. Blandford; Caroline Ryan
116.8 million (2005) to
The Lancet | 1998
Caroline Ryan; Ouk Vong Vathiny; Pamina M. Gorbach; Hor Bun Leng; Alain Berlioz-Arthaud; William L. H. Whittington; King K. Holmes
202.2 million (2008); and procurement increased from 6.2 million to 22.1 million monthly packs. The proportion spent on generic ARVs increased from 9.17% (95% confidence interval [CI], 9.17%-9.18%) in 2005 to 76.41% (95% CI, 76.41%-76.42%) in 2008 (P < .001), and the proportion of generic packs procured increased from 14.8% (95% CI, 14.79%-14.84%) in 2005 to 89.33% (95% CI, 89.32%-89.34%) in 2008 (P < .001). In 2008, there were 8 PEPFAR programs that procured at least 90.0% of ARV packs in generic form; South Africa had the lowest generic procurement (24.7%; 95% CI, 24.6%-24.8%). Procurement of generic fixed-dose combinations increased from 33.3% (95% CI, 33.24%-33.43%) in 2005 to 42.73% (95% CI, 42.71%-42.75%) in 2008. Estimated yearly savings generated through generic ARV use were
The Lancet | 2005
Anna Shakarishvili; Lk Dubovskaya; Ls Zohrabyan; J S St Lawrence; Sevgi O. Aral; Lg Dugasheva; Sa Okan; Js Lewis; Kathleen A. Parker; Caroline Ryan
8,108,444 in 2005,
PLOS Medicine | 2011
Kim Dickson; Nhan T. Tran; Julia Samuelson; Emmanuel Njeuhmeli; Peter Cherutich; Bruce Dick; Tim Farley; Caroline Ryan; Catherine Hankins
24,940,014 in 2006,
The Journal of Infectious Diseases | 2009
Gabriela Paz-Bailey; Maya Sternberg; Adrian Puren; Lauri E. Markowitz; Ronald C. Ballard; Sinead Delany; Sarah Hawkes; Okey C. Nwanyanwu; Caroline Ryan; David A. Lewis
75,645,816 in 2007, and
Journal of Acquired Immune Deficiency Syndromes | 2012
Jason Reed; Emmanuel Njeuhmeli; Anne Thomas; Melanie C. Bacon; Robert C. Bailey; Peter Cherutich; Kelly Curran; Kim E Dickson; Tim Farley; Catherine Hankins; Karin Hatzold; Zebedee Mwandi; Luke Nkinsi; Renee Ridzon; Caroline Ryan; Naomi Bock
214,648,982 in 2008, a total estimated savings of
AIDS | 2002
Pamina M. Gorbach; Caroline Ryan; Vonthanak Saphonn; Roger Detels
323,343,256. CONCLUSION Among PEPFAR-supported programs in 16 countries, availability of generic ARVs was associated with increased ARV procurement and substantial estimated cost savings.